Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis

Uri A. Liberman, Stuart R. Weiss, Johann Bröll, Helmut W. Minne, Hui Quan, Norman H. Bell, Jose Rodriguez-Portales, Robert W. Downs, Jan Dequeker, Murray Favus, Ego Seeman, Robert R. Recker, Thomas Capizzi, Arthur C. Santora, Antonio Lombardi, Raksha V. Shah, Laurence J. Hirsch, David B. Karpf

Research output: Contribution to journalArticle

2040 Citations (Scopus)

Abstract

Background. Postmenopausal osteoporosis is a serious health problem, and additional treatments are needed. Methods. We studied the effects of oral alendronate, an aminobisphosphonate, on bone mineral density and the incidence of fractures and height loss in 994 women with postmenopausal osteoporosis. The women were treated with placebo or alendronate (5 or 10 mg daily for three years, or 20 mg for two years followed by 5 mg for one year); all the women received 500 mg of calcium daily. Bone mineral density was measured by dual-energy x-ray absorptiometry. The occurrence of new vertebral fractures and the progression of vertebral deformities were determined by an analysis of digitized radiographs, and loss of height was determined by sequential height measurements. Results. The women receiving alendronate had significant, progressive increases in bone mineral density at all skeletal sites, whereas those receiving placebo had decreases in bone mineral density. At three years, the mean (±SE) differences in bone mineral density between the women receiving 10 mg of alendronate daily and those receiving placebo were 8.8±0.4 percent in the spine, 5.9±0.5 percent in the femoral neck, 7.8±0.6 percent in the trochanter, and 2.5±0.3 percent in the total body (P

Original languageEnglish
Pages (from-to)1437-1443
Number of pages7
JournalNew England Journal of Medicine
Volume333
Issue number22
DOIs
StatePublished - Nov 30 1995

Fingerprint

Alendronate
Postmenopausal Osteoporosis
Bone Density
Incidence
Placebos
Femur Neck
Femur
Spine
X-Rays
Calcium
Health

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., ... Karpf, D. B. (1995). Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. New England Journal of Medicine, 333(22), 1437-1443. https://doi.org/10.1056/NEJM199511303332201

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. / Liberman, Uri A.; Weiss, Stuart R.; Bröll, Johann; Minne, Helmut W.; Quan, Hui; Bell, Norman H.; Rodriguez-Portales, Jose; Downs, Robert W.; Dequeker, Jan; Favus, Murray; Seeman, Ego; Recker, Robert R.; Capizzi, Thomas; Santora, Arthur C.; Lombardi, Antonio; Shah, Raksha V.; Hirsch, Laurence J.; Karpf, David B.

In: New England Journal of Medicine, Vol. 333, No. 22, 30.11.1995, p. 1437-1443.

Research output: Contribution to journalArticle

Liberman, UA, Weiss, SR, Bröll, J, Minne, HW, Quan, H, Bell, NH, Rodriguez-Portales, J, Downs, RW, Dequeker, J, Favus, M, Seeman, E, Recker, RR, Capizzi, T, Santora, AC, Lombardi, A, Shah, RV, Hirsch, LJ & Karpf, DB 1995, 'Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis', New England Journal of Medicine, vol. 333, no. 22, pp. 1437-1443. https://doi.org/10.1056/NEJM199511303332201
Liberman, Uri A. ; Weiss, Stuart R. ; Bröll, Johann ; Minne, Helmut W. ; Quan, Hui ; Bell, Norman H. ; Rodriguez-Portales, Jose ; Downs, Robert W. ; Dequeker, Jan ; Favus, Murray ; Seeman, Ego ; Recker, Robert R. ; Capizzi, Thomas ; Santora, Arthur C. ; Lombardi, Antonio ; Shah, Raksha V. ; Hirsch, Laurence J. ; Karpf, David B. / Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. In: New England Journal of Medicine. 1995 ; Vol. 333, No. 22. pp. 1437-1443.
@article{d4002a5f509545a382a0e0db6913c623,
title = "Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis",
abstract = "Background. Postmenopausal osteoporosis is a serious health problem, and additional treatments are needed. Methods. We studied the effects of oral alendronate, an aminobisphosphonate, on bone mineral density and the incidence of fractures and height loss in 994 women with postmenopausal osteoporosis. The women were treated with placebo or alendronate (5 or 10 mg daily for three years, or 20 mg for two years followed by 5 mg for one year); all the women received 500 mg of calcium daily. Bone mineral density was measured by dual-energy x-ray absorptiometry. The occurrence of new vertebral fractures and the progression of vertebral deformities were determined by an analysis of digitized radiographs, and loss of height was determined by sequential height measurements. Results. The women receiving alendronate had significant, progressive increases in bone mineral density at all skeletal sites, whereas those receiving placebo had decreases in bone mineral density. At three years, the mean (±SE) differences in bone mineral density between the women receiving 10 mg of alendronate daily and those receiving placebo were 8.8±0.4 percent in the spine, 5.9±0.5 percent in the femoral neck, 7.8±0.6 percent in the trochanter, and 2.5±0.3 percent in the total body (P",
author = "Liberman, {Uri A.} and Weiss, {Stuart R.} and Johann Br{\"o}ll and Minne, {Helmut W.} and Hui Quan and Bell, {Norman H.} and Jose Rodriguez-Portales and Downs, {Robert W.} and Jan Dequeker and Murray Favus and Ego Seeman and Recker, {Robert R.} and Thomas Capizzi and Santora, {Arthur C.} and Antonio Lombardi and Shah, {Raksha V.} and Hirsch, {Laurence J.} and Karpf, {David B.}",
year = "1995",
month = "11",
day = "30",
doi = "10.1056/NEJM199511303332201",
language = "English",
volume = "333",
pages = "1437--1443",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "22",

}

TY - JOUR

T1 - Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis

AU - Liberman, Uri A.

AU - Weiss, Stuart R.

AU - Bröll, Johann

AU - Minne, Helmut W.

AU - Quan, Hui

AU - Bell, Norman H.

AU - Rodriguez-Portales, Jose

AU - Downs, Robert W.

AU - Dequeker, Jan

AU - Favus, Murray

AU - Seeman, Ego

AU - Recker, Robert R.

AU - Capizzi, Thomas

AU - Santora, Arthur C.

AU - Lombardi, Antonio

AU - Shah, Raksha V.

AU - Hirsch, Laurence J.

AU - Karpf, David B.

PY - 1995/11/30

Y1 - 1995/11/30

N2 - Background. Postmenopausal osteoporosis is a serious health problem, and additional treatments are needed. Methods. We studied the effects of oral alendronate, an aminobisphosphonate, on bone mineral density and the incidence of fractures and height loss in 994 women with postmenopausal osteoporosis. The women were treated with placebo or alendronate (5 or 10 mg daily for three years, or 20 mg for two years followed by 5 mg for one year); all the women received 500 mg of calcium daily. Bone mineral density was measured by dual-energy x-ray absorptiometry. The occurrence of new vertebral fractures and the progression of vertebral deformities were determined by an analysis of digitized radiographs, and loss of height was determined by sequential height measurements. Results. The women receiving alendronate had significant, progressive increases in bone mineral density at all skeletal sites, whereas those receiving placebo had decreases in bone mineral density. At three years, the mean (±SE) differences in bone mineral density between the women receiving 10 mg of alendronate daily and those receiving placebo were 8.8±0.4 percent in the spine, 5.9±0.5 percent in the femoral neck, 7.8±0.6 percent in the trochanter, and 2.5±0.3 percent in the total body (P

AB - Background. Postmenopausal osteoporosis is a serious health problem, and additional treatments are needed. Methods. We studied the effects of oral alendronate, an aminobisphosphonate, on bone mineral density and the incidence of fractures and height loss in 994 women with postmenopausal osteoporosis. The women were treated with placebo or alendronate (5 or 10 mg daily for three years, or 20 mg for two years followed by 5 mg for one year); all the women received 500 mg of calcium daily. Bone mineral density was measured by dual-energy x-ray absorptiometry. The occurrence of new vertebral fractures and the progression of vertebral deformities were determined by an analysis of digitized radiographs, and loss of height was determined by sequential height measurements. Results. The women receiving alendronate had significant, progressive increases in bone mineral density at all skeletal sites, whereas those receiving placebo had decreases in bone mineral density. At three years, the mean (±SE) differences in bone mineral density between the women receiving 10 mg of alendronate daily and those receiving placebo were 8.8±0.4 percent in the spine, 5.9±0.5 percent in the femoral neck, 7.8±0.6 percent in the trochanter, and 2.5±0.3 percent in the total body (P

UR - http://www.scopus.com/inward/record.url?scp=0028851590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028851590&partnerID=8YFLogxK

U2 - 10.1056/NEJM199511303332201

DO - 10.1056/NEJM199511303332201

M3 - Article

VL - 333

SP - 1437

EP - 1443

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 22

ER -